SARA SAMESHIMA: Open Payments
NPI 1720576473 · LOS GATOS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,838 in 73 payments from 11 companies in 2025. Trend: 2023 $881 · 2024 $1,808 · 2025 $1,838
Food & beverage: $1,838
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $661 |
| Madrigal Pharmaceuticals | 15 | $491 |
| Janssen Biotech, Inc. | 13 | $311 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $108 |
| QOL Medical, LLC | 4 | $94 |
| Aimmune Therapeutics, Inc. | 2 | $55 |
| Novo Nordisk Inc | 1 | $32 |
| Ardelyx, Inc. | 1 | $28 |
| Lilly USA, LLC | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
Products named: REZDIFFRA, TREMFYA, LINZESS, RINVOQ, CREON, XIFAXAN, SKYRIZI, Sucraid.
Industry payments across CA — which companies pay providers there.
